Top Markets
Coin of the day
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Clasificación en acciones #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Precio por acción
$43.48
Capitalización bursátil
$8.97B
Cambio (1 día)
0.37%
Cambio (1 año)
192.01%
País
US
Comercio Immunovant, Inc. (IMVT)

Categoría

Historial de desdoblamientos de acciones de Immunovant, Inc. (IMVT)
La acción Immunovant, Inc. (símbolo: IMVT) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 25, 2026.
Una acción IMVT comprada antes de Aug 25, 2026 equivaldría hoy a 0 acciones IMVT.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH